Why it isn't too late to buy ResMed shares

Goldman Sachs believes this top stock could keep climbing.

| More on:
a woman holds her hands up in delight as she sits in front of her lap

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares have been on a strong run this month.

Since the start of January, the sleep treatment company's shares have risen 10.5%.

A good portion of this gain came last week after ResMed impressed the market with its second quarter update.

Can ResMed shares keep rising?

The good news for investors is that the team at Goldman Sachs believes the company's shares can still rise materially from current levels.

According to a note, the broker has responded to ResMed's quarterly update by reiterating its buy rating and lifting its price target to $33.50.

Based on the current ResMed share price of $28.45, this implies potential upside of 18% for investors over the next 12 months.

Commenting on the quarter, Goldman said:

RMD reported solid +4-6% earnings beats at 2Q24 as US device growth recovered back to/above market growth, whilst the pace of gross margin recovery exceeded our expectations.

Goldman also addressed concerns over gross margins, competitive dynamics, and the impact of GLP-1s such as Ozempic. It said:

Taking a higher-level view beyond the quarter, the three primary debates that have dominated investor focus over the last 12+ months have been: 1) the potential impact of further GLP-1 adoption on CPAP demand/adherence; 2) the shape of GM recovery, and if/when RMD can return to pre-Covid profitability; and 3) competitive dynamics amongst incumbents, particularly the magnitude of impact if/when PHIA re-enters the US CPAP markets. On all three points we believe there is sufficient positivity to continue to see asymmetric upside risk at current valuations and, overall, we saw nothing today to change our fundamental views.

Overall, the broker sees ResMed as a top option for investors right now despite its strong gains this month.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »